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Carsten Schleh1, Wolfgang G Kreyling2* and Claus-Michael Lehr3Abstract
The article of Gasser et al. [Part Fibre Toxicol. 24; 9:17, 2012] describes the interaction of carbon nanotubes with
cells within a complex cell culture model. Besides various toxicity parameters, the influence of coating with
pulmonary surfactant was investigated. Pulmonary surfactant covers the entire alveolar region with the main
function of decreasing the surface tension in the alveoli to prevent alveolar collapse. Although each inhaled
nanoparticle, reaching the alveoli, will come into contact with pulmonary surfactant which will probably lead to a
surfactant coating, pulmonary surfactant components are not commonly integrated in in vitro systems. Gasser and
co-workers have shown that this surfactant coating is able to influence the further interaction with cellular systems.
Hence, each scientist, working with in vitro systems and nanoparticles, should think of integrating pulmonary
surfactant structures in order to harmonize the in vitro systems with the in vivo situation. In the present
commentary we discuss the most important points of the manuscript of Gasser et al. and discuss where the usage
of pulmonary surfactant can be further optimized.
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The article of Gasser and co-workers [1] describes the
interaction of carbon nanotubes (CNTs) with an in vitro
cell culture model – uptake of CNTs as well as their
ability to cause oxidative stress, cytokine/chemokine
release and induction of apoptosis were evaluated. In
some experiments, CNTs were pre-coated with the
porcine pulmonary surfactant preparation CurosurfW
before incubation with the in vitro system.Main text
CurosurfW is a commonly used pulmonary surfactant
preparation [2,3]. The influence of this surfactant-
coating on the interaction with an in vitro cell system
was recently investigated by Gasser et al. [1]. Although
the described experimental approach is very simple and
easy to perform, the obtained results are very important
and bring more light into the darkness of what are the
crucial factors in nanoparticle toxicity. Furthermore,
these experiments display an important step in making* Correspondence: kreyling@helmholtz-muenchen.de
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reproduction in any medium, provided the orin vitro systems more similar to the in vivo gold
standard.
Pulmonary surfactant consists of phospholipids and the
four surfactant proteins (SP)-A, -B, –C, and -D. It covers
the entire alveolar region with the main function of
decreasing the surface tension in the alveoli to prevent
alveolar collapse. Furthermore, surfactant components
participate in the immune defence. Each individual
inhaled nanoparticle, which reaches the alveolar region,
will always impinge on pulmonary surfactant. Pulmonary
surfactant is thereby the first contact of the human body
with the inhaled nanoparticle. This first contact leads to a
coating of the nanoparticle with surfactant lipids [4,5] and
also surfactant proteins [6-10]. No uncoated nanoparticle
will ever reach lung cells. Since nanoparticles interact by
means of their surface with their environment the respect-
ive coating will consequently influence the interaction of
the inhaled particles with lung cells. Within the present
manuscript the group of Barbara Rothen-Rutishauser has
clearly shown that surfactant-coating of CNT is able to
change their toxic behaviour. Hence, the investigation of
the influence of this surfactant coating is not only conse-
quent but an absolute must in order to understand the
mechanism of nanoparticle toxicity. This altered toxicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Schleh et al. Particle and Fibre Toxicology 2013, 10:6 Page 2 of 3
http://www.particleandfibretoxicology.com/content/10/1/6behaviour may be due to a changed direct interaction with
the cells or due to an affected uptake of NP into individual
cells [11,12].
This knowledge will increase our competence to
engineer safe nanoparticles which serve but do not
harm humans and should be expanded to other research
groups performing in vitro testing. The development of
viable alternatives to in vivo tests is one of the five grand
challenges in nanotechnology as postulated by Maynard
et al. [13] to evaluate the toxicity of engineered
nanomaterials during the next 15 years. Although
several in vitro systems exist and although there is no
doubt that most of these systems lead to a good first
insight into the toxicity or even to a better mechanistic
understanding of the toxicity there is also no doubt that
these systems have to be optimized in the future. A valid
alternative to the gold standard in toxicity testing – the
in vivo system – has to be created. Such in vivo-near
in vitro systems will lead to:
– decreased costs compared to expensive in vivo
studies,
– results within a relatively short time,
– and also to an optimized animal welfare due to
minimising animal testing.
Besides the simple in vitro monocultures complex co-
culture systems – like the model in the present study of
Gasser et al. – can be used. However, as we know from
the present manuscript a relevant coating of the
nanoparticles should be used in order to optimize in vitro
testing. Especially when focusing on the lung a surfactant
coating should always be integrated in the experimental
design. Furthermore, more details should be optimized in
order to reach a fine tuning of the experimental approach.
In the experiments of the present manuscript, the CNTs
where first coated with surfactant and then pipetted into
the medium of the submersed cell culture. This simulates
not directly the in vivo situation where particles impinge
on the surfactant layer and afterwards are pushed into the
aqueous hypophase by surface forces [4,14]. In this
hypophase nanoparticles come into contact with various
surfactant- and also other proteins which may interact
with the surfactant phospholipid layer at the outer particle
surface. In the present submerse cell culture model just
components from the cell culture medium exist which
may interact with the CNTs and its phospholipid coating.
The biggest source for proteins in cell culture media is
added serum (e.g. fetal calf serum), which was not incor-
porated in the study of Gasser et. al. However, in the
RPMI1640 medium, which was used in the present study,
also peptides like gluthatione are present which of course
may interact with the particles or fibres. This scenario
does not resemble the in vivo situation. Hence, air liquidinterface models with a thin surfactant layer at the top
should be the preferred choice when working with in vitro
models to investigate the toxic effects of nanoparticles.
Furthermore, although CurosurfW is a suitable model for
pulmonary surfactant, it is not ideal and a better alterna-
tive should be found. CurosurfW mainly contains lipids
and the surfactant proteins B and C. The surfactant pro-
teins -A and-D are hardly found. Since it is known, that
SP-A and SP-D bind to nanoparticles and may influence
the toxicity, uptake into cells as well as biodistribution of
nanoparticles [8,15] a surfactant preparation containing
phospholipids as well as all four surfactant proteins should
be found. However, due to the general method of surfac-
tant isolation a balanced presence of the proteins is rather
complicated since SP-A and –D are hydrophilic while SP-
C and –B are lipophilic. Further surfactant preparations
are commercially available and the most common are
Alveofact, Infasurf, and Survanta. As Curosurf, none of
the other commercial surfactants contain SP-A and SP-D
since all are lipid extracts. Furthermore, they differ regard-
ing their amount of SP-B and SP-C, the phospholipid
composition as well as the source (Curosurf is porcine;
Alveofact, Infasurf, and Survanta are bovine). Due to the
different concentrations of proteins and phospholipids a
differed interaction with the particles and subsequently a
different outcome of the toxicological response can be
expected. An even more in vivo like situation may be
given, if not a commercially available surfactant prepar-
ation is used but lung lavage fluid in which also SP-D and
SP-A among all other lung lining fluid proteins are
available.
Since the coating of proteins on the particles surface is
not a static but a dynamic process, depending on affinities,
quantities and of course kind of available proteins, the
usage of different surfactant preparations or lavage fluids
will lead to different binding dynamics on the surface of
the particle. Furthermore, also lipids compete for the
space at the particles surface. Additionally, proteins can
bind directly on lipids bound on the surface. Hence, since
the bound proteins or lipids will come into contact with
cellular structures, these dynamics influence the toxic
response and the best surfactant preparation or lavage
fluid has to be investigated in order to mimic the in vivo
situation in an in vitro model.
Besides the direct interaction with lung cells after
inhalation, surfactant coating is also able to determine
the toxic effects in secondary target organs like the liver:
1) The initial coating in the surfactant layer will
influence the subsequent interactions with cell and
organ membranes leading to dynamic exchange of
the particle coating and hence continues to affect
the biodistributional fate of the particle in the
various organs and tissues.
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organs is influenced by coating. It is clearly known, that
nanoparticles can cross the air-blood barrier to reach
nearly each organ [16] and that coating of nanoparticles
influences this biodistribution. Hence, since surfactant is
at least the initial coating of the nanoparticles, it will
determine the toxic response in secondary target
organs. Although we know that proteins and lipids at
the surface of the nanoparticle are exchanged by time,
the initial coating has a significant influence on this
process [17]. This should be considered for in vitro
experiments with e.g. liver cells.
At the end it is important to note, that not only sur-
factant is able to modify the particles mode of harm in
cellular structure but also particles are able to affect the
function of pulmonary surfactant. This is especially
known for biophysical surfactant function when particles
increased the surface tension at the air-liquid interface
of pulmonary surfactant [18-20].
Discussion and conclusion
The following take home messages can be concluded:
1) Inhaled nanoparticles which deposit in the alveoli
will be coated with pulmonary surfactant
2) Pulmonary surfactant coating is able to influence the
toxic response in the lung and also in secondary
target organs
3) An suitable experimental step of pulmonary surfactant
coating should be integrated in optimised in vitro
systems in order to simulate the in vivo situation
Abbreviations
CNTs: Carbon nanotubes; SP: Surfactant proteins.
Competing interests
The authors have declared that no competing interests exist.
Authors’ contributions
CS drafted the manuscript, WGK and CML revised the manuscript critically
for important intellectual content. All authors read and approved the final
manuscript.
Author details
1Department of in vivo Pharmacology/Toxicology, BSL BIOSERVICE Scientific
Laboratories GmbH, Behringstr, 6/8, Planegg/Munich 82152, Germany.
2Institute of Epidemiology II, Helmholtz Center Munich – German Research
Center for Environmental Health, D-85764, Neuherberg/Munich, Germany.
3Helmholtz institut for Pharmaceutical Research Saarland (HIPS), Helmholtz
Center for Infection Research (HZI), Saarland University, 66123, Saarbrücken,
Germany.
Received: 24 September 2012 Accepted: 15 March 2013
Published: 25 March 2013
References
1. Gasser M, Wick P, Clift MJ, Blank F, Diener L, Yan B, Gehr P, Krug HF, Rothen-
Rutishauser B: Pulmonary surfactant coating of multi-walled carbon
nanotubes (MWCNTs) influences their oxidative and pro-inflammatory
potential in vitro. Part Fibre Toxicol 2012, 9:17.2. Schleh C, Muhlfeld C, Pulskamp K, Schmiedl A, Nassimi M, Lauenstein HD,
Braun A, Krug N, Erpenbeck VJ, Hohlfeld JM: The effect of titanium dioxide
nanoparticles on pulmonary surfactant function and ultrastructure.
Respir Res 2009, 10:90.
3. Calkovska A, Linderholm B, Haegerstrand-Bjorkman M, Curstedt T:
Properties of modified natural surfactant after exposure to fibrinogen
in vitro and in animal model of respiratory distress syndrome. Pediatr Res
2012, 72(3):262–269.
4. Muhlfeld C, Rothen-Rutishauser B, Blank F, Vanhecke D, Ochs M, Gehr P:
Interactions of nanoparticles with pulmonary structures and cellular
responses. Am J Physiol Lung Cell Mol Physiol 2008, 294:L817–L829.
5. Kapralov AA, Feng WH, Amoscato AA, Yanamala N, Balasubramanian K,
Winnica DE, Kisin ER, Kotchey GP, Gou P, Sparvero LJ, et al: Adsorption of
surfactant lipids by single-walled carbon nanotubes in mouse lung upon
pharyngeal aspiration. ACS Nano 2012, 6:4147–4156.
6. Schleh C, Hohlfeld JM: Interaction of nanoparticles with the pulmonary
surfactant system. Inhal Toxicol 2009, 21:97–103.
7. Schleh C, Rothen-Rutishauser B, Kreyling WG: The influence of pulmonary
surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm
2011, 77(3):350–352.
8. Ruge CA, Schaefer UF, Herrmann J, Kirch J, Canadas O, Echaide M, Perez-Gil J,
Casals C, Muller R, Lehr CM: The interplay of lung surfactant proteins and
lipids assimilates the macrophage clearance of nanoparticles. PLoS One
2012, 7:e40775.
9. Schulze C, Schaefer UF, Ruge CA, Wohlleben W, Lehr CM: Interaction of
metal oxide nanoparticles with lung surfactant protein A. Eur J Pharm
Biopharm 201, 77(3):376–383.
10. Ruge CA, Kirch J, Canadas O, Schneider M, Perez-Gil J, Schaefer UF, Casals C,
Lehr CM: Uptake of nanoparticles by alveolar macrophages is triggered
by surfactant protein A. Nanomed Nanotech Biol Med 2011, 7:690–693.
11. Kumar P, Bohidar HB: Interaction of soot derived multi-carbon
nanoparticles with lung surfactants and their possible internalization
inside alveolar cavity, Indian. J Exp Biol 2010, 48(10):1037–1042.
12. Vranic S, Garcia-Verdugo I, Darnis C, Sallenave JM, Boggetto N, Marano F,
Boland S, Baeza-Squiban A: Internalization of SiO(2) nanoparticles by
alveolar macrophages and lung epithelial cells and its modulation by
the lung surfactant substitute Curosurf(W). Environ Sci Pollut Res Int 2013
[Epub ahead of print].
13. Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdorster G,
Philbert MA, Ryan J, Seaton A, Stone V, et al: Safe handling of
nanotechnology. Nature 2006, 444(7117):267–269.
14. Gehr P, Geiser M, Im Hof V, Schurch S, Waber U, Baumann M: Surfactant
and inhaled particles in the conducting airways: structural, stereological,
and biophysical aspects. Microsc Res Tech 1993, 26:423–436.
15. Schleh C, Holzwarth U, Hirn S, Wenk A, Simonelli F, Schäffler M, Möller W,
Gibson N, Kreyling WG: Biodistribution of inhaled gold nanoparticles and
the influence of surfactant protein D. J Aerosol Med Pulm Drug Deliv 2013,
26(1):24–30.
16. Kreyling WG, Hirn S, Schleh C: Nanoparticles in the lung. Nat Biotechnol
2010, 28:1275–1276.
17. Gasser M, Rothen-Rutishauser B, Krug HF, Gehr P, Nelle M, Yan B, Wick P:
The adsorption of biomolecules to multi-walled carbon nanotubes is
influenced by both pulmonary surfactant lipids and surface chemistry.
J Nanobiotechnol 2010, 8:31.
18. Schleh C, Mühlfeld C, Pulskamp K, Schmiedl A, Nassimi M, Lauenstein HD,
Braun A, Krug N, Erpenbeck VJ, Hohlfeld JM: The effect of titanium dioxide
nanoparticles on pulmonary surfactant function and ultrastructure.
Respir Res 2009, 30:10–90.
19. Bakshi MS, Zhao L, Smith R, Possmayer F, Petersen NO: Metal nanoparticle
pollutants interfere with pulmonary surfactant function in vitro. Biophys J
2008, 94(3):855–68.
20. Kondej D, Sosnowski TR: Alteration of biophysical activity of pulmonary
surfactant by aluminosilicate nanoparticles. Inhal Toxicol 2013, 25(2):77–83.
doi:10.1186/1743-8977-10-6
Cite this article as: Schleh et al.: Pulmonary surfactant is indispensable
in order to simulate the in vivo situation. Particle and Fibre Toxicology
2013 10:6.
